

Supplemental Table 1: BTK and PLCG2 mutations in patients at baseline and at time of progression		
Pt #	BTK-Baseline	BTK- At time of progression
1	BTK (C481S 2%)	BTK (L528W, 78%)
2	BTK C481R	N/A
3	BTK (C481S, C481S, T474I)	BTK (T474I 73%, V416K 5%, V416I 5%)
4	BTK (C481R, 5%)	BTK (L528W, 72%)
5	BTK (C481S 5%, C481S 63%)	BTK (T474I, 87%)
6	BTK C481R	N/A
7	BTK (C481F 23%, C481S 18%)	BTK (L528W 93%)
8	BTK (T474I, C481R 5%)	BTK (T474I 9%)
9	BTK (C481S 5%, C481R 18%); PLCG2 (D993G 7%, M1141K 7%)	BTK (C481S 5%, C481R 12%); PLCG2 (M1141K < 5%)
10	BTK(C481R)	BTK (L528W 7%, C481R 12%, T474I 83%)
11	BTK (C481S, 6%)	BTK (T474I, 28%)
12	WT	WT
13	WT	WT
14	WT	BTK (L528W 23%, A428D 11%)